As the first MAH (Marketing Authorization Holder) product owned by DiQi Pharmaceuticals Co., Ltd, the pregabalin orally disintegrating tablets mark a significant step forward in DiQi's transition from drug development to commercialization, representing a major milestone in the company's growth.
 

Prelamine is a new-generation neuropathic pain treatment that acts on voltage-gated calcium channels in the nervous system, reducing excessive release of excitatory neurotransmitters and inhibiting hyperalgesia. Currently, Prelibrin has become a first-line treatment for postherpetic neuralgia and fibromyalgia both domestically and internationally.^[1][2][3]、A second-line adjunctive therapy for partial-onset seizures, it is also widely used for various other types of neuropathic pain, such asDiabetic Peripheral NeuropathyPain, post-operative neuropathic pain, post-traumatic neuropathic pain, cancer-related neuropathic pain, chemotherapy-induced neuropathic pain^[1]。

Due to the presence of pregabalin orally disintegrating tablets,Easy to take (rapidly dissolves in the mouth without needing water to swallow), convenient to carry, and fast-acting.，Particularly suitable for individuals with swallowing difficulties or elderly patients，Significantly improved patient medication adherence.

The launch of pregabalin orally disintegrating tablets marks a significant milestone for DiQi Pharmaceuticals Co., Ltd. inThe field of neurotherapyis a crucial step in pipeline development. Moving forward, DiQi Pharmaceuticals Co., Ltd will continue to uphold the principles of “Science, Efficiency, and Innovation” to provide patients with more diverse and personalized medication options. We are committed to developing and manufacturing high-quality, effective, long-acting, and highly compliant medicines that are affordable for the public!


References

[2] 2021年《中国纤维肌痛康复指南》

[4] 2016年《带状疱疹后神经痛诊疗中国专家共识》

[6] 2013年《关于成人癫痫患者长程管理的专家共识》

<p style="margin: 0px; padding: 0px; outline: 0px; max-width: 100%; box-sizing: border-box; clear: both; min-height: 1em; color: rgb(117, 117, 117); font-family: system-ui, -apple-system, BlinkMacSystemFont, " helvetica="" neue",="" "pingfang="" sc",="" "hiragino="" sans="" gb",="" "microsoft="" yahei="" ui",="" yahei",="" arial,="" sans-serif;="" font-size:="" 14px;="" letter-spacing:="" 0.544px;="" text-align:="" justify;="" overflow-wrap:="" break-word="" !important;"="">[7] 2022年《中国成人局灶性癫痫规范化诊治指南》